{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:15:26Z","timestamp":1779210926039,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,16]],"date-time":"2021-03-16T00:00:00Z","timestamp":1615852800000},"content-version":"vor","delay-in-days":74,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2021.100357","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T21:01:00Z","timestamp":1616101260000},"page":"100357","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Ponatinib-associated panniculitis: Case report and review of the literature"],"prefix":"10.1016","volume":"27","author":[{"given":"Daniel","family":"Antwi-Amoabeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joban","family":"Ghuman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine","family":"Ghuman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryce D.","family":"Beutler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark B.","family":"Ulanja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Kuriakose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2021.100357_bib0001","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719826444","article-title":"Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia","volume":"10","author":"Molica","year":"2019","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100357_bib0002","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S1470-2045(16)00080-2","article-title":"Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial","volume":"17","author":"Lipton","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100357_bib0003","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.ctarc.2021.100357_bib0004","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.revmed.2016.05.008","article-title":"Panniculites cutan\u00e9es [Cutaneous panniculitis]","volume":"37","author":"Velter","year":"2016","journal-title":"Rev Med Interne"},{"issue":"4","key":"10.1016\/j.ctarc.2021.100357_bib0005","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/j.1529-8019.2010.01333.x","article-title":"Infection and panniculitis","volume":"23","author":"Morrison","year":"2010","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100357_bib0006","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1053\/j.semdp.2016.12.004","article-title":"Panniculitis: a summary","volume":"34","author":"Wick","year":"2017","journal-title":"Semin Diagn Pathol"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100357_bib0007","first-page":"263","article-title":"Drug-induced panniculitides","volume":"149","author":"Borroni","year":"2014","journal-title":"G Ital Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.ctarc.2021.100357_bib0008","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/cup.12326","article-title":"Ponatinib-induced neutrophilic panniculitis","volume":"41","author":"Zhang","year":"2014","journal-title":"J Cutan Pathol"},{"issue":"24","key":"10.1016\/j.ctarc.2021.100357_bib0009","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1056\/NEJMc053425","article-title":"Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia","volume":"354","author":"Assouline","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctarc.2021.100357_bib0010","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1046\/j.1365-2133.2003.05594.x","article-title":"Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib","volume":"149","author":"Ugurel","year":"2003","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100357_bib0011","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.annder.2010.11.009","volume":"138","author":"de Masson","year":"2011","journal-title":"Ann Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100357_bib0012","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1001\/jamaoncol.2015.0457","article-title":"Panniculitis in patients undergoing treatment with the bruton tyrosine kinase inhibitor ibrutinib for lymphoid leukemias","volume":"1","author":"Fabbro","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctarc.2021.100357_bib0013","article-title":"Panniculitis in a patient with metastatic renal cell carcinoma on a tyrosine kinase inhibitor","author":"Nafissi","year":"2020","journal-title":"Anticancer Drugs"},{"issue":"6","key":"10.1016\/j.ctarc.2021.100357_bib0014","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jdcr.2020.04.016","article-title":"Use of etanercept in management of tyrosine kinase-inhibitor-induced erythema nodosum","volume":"6","author":"Alia","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"5","key":"10.1016\/j.ctarc.2021.100357_bib0015","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaad.2005.03.001","article-title":"Subcutaneous Sweet's syndrome: a variant of acute febrile neutrophilic dermatosis that is included in the histopathologic differential diagnosis of neutrophilic panniculitis","volume":"52","author":"Cohen","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ctarc.2021.100357_bib0016","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.critrevonc.2017.09.016","article-title":"Hand-foot skin reaction with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis","volume":"119","author":"Li","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100357_bib0017","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1053\/j.seminoncol.2006.01.011","article-title":"Autoimmune complications of chronic lymphocytic leukemia","volume":"33","author":"Hamblin","year":"2006","journal-title":"Semin Oncol"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100357_bib0018","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/cancers12020282","article-title":"Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs","volume":"12","author":"Vitale","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100357_bib0019","doi-asserted-by":"crossref","first-page":"16357","DOI":"10.1038\/s41598-020-73131-y","article-title":"Chronic lymphocytic leukemia-associated paraneoplastic pemphigus: potential cause and therapeutic strategies","volume":"10","author":"Cao","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ctarc.2021.100357_bib0020","first-page":"235","article-title":"Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases","volume":"67","author":"D\u00fchrsen","year":"1987","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100357_bib0021","first-page":"45","article-title":"Drug-induced acute pancreatitis: a review","volume":"15","author":"Jones","year":"2015","journal-title":"Ochsner J"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221000551?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221000551?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:25:50Z","timestamp":1762842350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294221000551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":21,"alternative-id":["S2468294221000551"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100357","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ponatinib-associated panniculitis: Case report and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100357","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100357"}}